

## **ReciBioPharm unveils ground-breaking, real-time PAT platform at Bio Summit**

- *Reduces time in analytical testing and quality control*
- *Enables faster, smarter delivery of medicines through real-time process analytics*
- *Supports both process development and large-scale commercial manufacturing*
- *ReciBioPharm is Recipharm's Advanced Bio segment.*

ReciBioPharm, Recipharm's Advanced Bio segment, a leading global contract development and manufacturing organisation, is proud to unveil its novel Process Analytical Technology (PAT), a next-generation platform for real-time process analytics and intelligent manufacturing, at this year's Bio Summit.

Born from the development of Recipharm's xRNA continuous manufacturing line, this innovative PAT platform marks a major advancement in modern quality control. Designed to be mobile, modular, and smart, the platform transforms analytical testing.

Dubbed "QC on Wheels", the PAT system centralises quality analytics on a mobile skid, integrating multiple advanced technologies with proprietary orchestration and management software. This software converts in-process raw data into actionable, real-time insights, empowering operators and reducing the time from development to patient delivery.

Vikas Gupta, President of ReciBioPharm, Recipharm's Advanced Biologics segment, said: "We designed the PAT platform to fundamentally shift how manufacturers approach analytical testing. It's about putting insights directly into the hands of those running the process, optimising quality in real time, and enabling scalable, sustainable biomanufacturing."

The stackable, compact system is vendor-agnostic, modality-flexible, and future-proof, built to support existing and emerging analytical technologies. Its open-source modelling library supports diverse machine learning, mechanistic, and hybrid models. This prelaunch version can run multiple analyses concurrently and is configurable to support commercial-scale applications across therapeutic modalities.

Whether for process development or large-scale commercial manufacturing, ReciBioPharm's PAT platform reduces overall process footprint, boosts efficiency, and cuts waste, paving the way for faster, more intelligent delivery of medicines.



### **For more information**

#### About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development.

Its Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US.

For more information on Recipharm, please visit [www.recipharm.com](http://www.recipharm.com) and [www.recibiopharm.com](http://www.recibiopharm.com)

#### **Media contact:**

Guenaëlle Holloway, Head of communications  
[Guenaëlle.Holloway@recipharm.com](mailto:Guenaëlle.Holloway@recipharm.com)  
+44 7730 303 708